Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.

The approval process for antibody biosimilars relies primarily on comprehensive analytical data to establish comparability and high similarity with the originator. Mass spectrometry (MS) in combination with liquid chromatography (LC) and electrophoretic methods are the corner stone for comparability and biosimilarity evaluation. In this special feature we report head-to-head comparison of trastuzumab and cetuximab with corresponding biosimilar and biobetter candidates based on cutting-edge mass spectrometry techniques such as native MS and ion-mobility MS at different levels (top, middle and bottom). In addition, we discuss the advantages and the limitations of sample preparation and enzymatic digestion, middle-up and -down strategies and the use of hydrogen/deuterium exchange followed by MS (HDX-MS). Last but not least, emerging separation methods combined to MS such as capillary zone electrophoresis-tandem MS (CESI-MS/MS), electron transfer dissociation (ETD), top down-sequencing (TDS) and high-resolution MS (HR-MS) that complete the panel of state-of-the-art MS-based options for comparability and biosimilarity evaluation are presented.

[1]  Yannis-Nicolas François,et al.  Full antibody primary structure and microvariant characterization in a single injection using transient isotachophoresis and sheathless capillary electrophoresis-tandem mass spectrometry. , 2014, Analytical chemistry.

[2]  D. Suckau,et al.  Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques , 2013, mAbs.

[3]  Davy Guillarme,et al.  Theory and practice of size exclusion chromatography for the analysis of protein aggregates. , 2014, Journal of pharmaceutical and biomedical analysis.

[4]  Janice M Reichert,et al.  Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies , 2011, mAbs.

[5]  C. Schneider,et al.  Biosimilars entering the clinic without animal studies , 2014, mAbs.

[6]  C. Damen,et al.  Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab , 2009, Journal of the American Society for Mass Spectrometry.

[7]  J. Reichert,et al.  European Medicines Agency workshop on biosimilar monoclonal antibodies , 2009, mAbs.

[8]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[9]  Marie-Paule Lefranc,et al.  Human immunoglobulin allotypes , 2009, mAbs.

[10]  Roy Jefferis,et al.  Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.

[11]  François Debaene,et al.  Analytical characterization of biosimilar antibodies and Fc-fusion proteins , 2013 .

[12]  T. Wurch,et al.  Editorial [Hot Topic: Therapeutic Antibodies and Derivatives: From the Bench to the Clinic(Guest Editor: Alain Beck)] , 2008 .

[13]  B. Kabakoff,et al.  Identification of multiple sources of charge heterogeneity in a recombinant antibody. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[14]  B. Karger,et al.  Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches , 2013, mAbs.

[15]  Jingming Zhang,et al.  Conformational characterization of the charge variants of a human IgG1 monoclonal antibody using H/D exchange mass spectrometry , 2013, mAbs.

[16]  A. Heck,et al.  Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry , 2014, Nature Protocols.

[17]  Alain Beck,et al.  Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. , 2009, Analytical biochemistry.

[18]  S. Sanglier-Cianférani,et al.  Extending mass spectrometry contribution to therapeutic monoclonal antibody lead optimization: characterization of immune complexes using noncovalent ESI-MS. , 2009, Analytical chemistry.

[19]  Alain Van Dorsselaer,et al.  Characterization of therapeutic antibodies and related products. , 2013, Analytical chemistry.

[20]  Alain Beck,et al.  Analysis of monoclonal antibody by a novel CE‐UV/MALDI‐MS interface , 2014, Electrophoresis.

[21]  Alain Van Dorsselaer,et al.  Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. , 2012, Analytical chemistry.

[22]  Jingming Zhang,et al.  An innovative approach for the characterization of the isoforms of a monoclonal antibody product , 2011, mAbs.

[23]  P. Schnier,et al.  Resolving disulfide structural isoforms of IgG2 monoclonal antibodies by ion mobility mass spectrometry. , 2010, Analytical chemistry.

[24]  W. Xu,et al.  Method to convert N-terminal glutamine to pyroglutamate for characterization of recombinant monoclonal antibodies. , 2013, Analytical biochemistry.

[25]  Ya-jun Guo,et al.  Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products , 2012, mAbs.

[26]  Aston Liu,et al.  Understanding the conformational impact of chemical modifications on monoclonal antibodies with diverse sequence variation using hydrogen/deuterium exchange mass spectrometry and structural modeling. , 2014, Analytical chemistry.

[27]  Guodong Chen,et al.  Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications. , 2014, Drug discovery today.

[28]  Vasco Filipe,et al.  Mass Spectrometric Analysis of Intact Human Monoclonal Antibody Aggregates Fractionated by Size-Exclusion Chromatography , 2010, Pharmaceutical Research.

[29]  Massimiliano Porrini,et al.  Dynamics of intact immunoglobulin G explored by drift-tube ion-mobility mass spectrometry and molecular modeling. , 2014, Angewandte Chemie.

[30]  S. Berkowitz,et al.  The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies. , 2011, Journal of pharmaceutical sciences.

[31]  Ya-jun Guo,et al.  Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors , 2011, mAbs.

[32]  Hongwei Xie,et al.  Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies , 2010, mAbs.

[33]  Alain Beck,et al.  GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins , 2010, Expert opinion on drug discovery.

[34]  Alain Van Dorsselaer,et al.  The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[35]  Y. Tsybin.  From high- to super-resolution mass spectrometry. , 2014, Chimia.

[36]  Quynh-Thu Le,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[37]  François Debaene,et al.  Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and "bispecific" monoclonal antibody formation. , 2013, Analytical chemistry.

[38]  L. Makowski,et al.  Investigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurements. , 2013, Journal of pharmaceutical sciences.

[39]  C. Fritsch,et al.  Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab , 2013, BioDrugs.

[40]  Yannis-Nicolas François,et al.  Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry , 2014, mAbs.

[41]  Li Yang,et al.  Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. , 2007, Analytical biochemistry.

[42]  J. Reichert,et al.  Approval of the first biosimilar antibodies in Europe , 2013, mAbs.

[43]  C. Schneider,et al.  Setting the stage for biosimilar monoclonal antibodies , 2012, Nature Biotechnology.

[44]  T. Wurch,et al.  9th Annual European Antibody Congress, November 11–13, 2013, Geneva, Switzerland , 2014, mAbs.

[45]  B. Meyer,et al.  Unambiguous characterization of N-glycans of monoclonal antibody cetuximab by integration of LC-MS/MS and ¹H NMR spectroscopy. , 2014, Analytical chemistry.

[46]  Alain Van Dorsselaer,et al.  Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[47]  A. Beck,et al.  Middle-down analysis of monoclonal antibodies with electron transfer dissociation orbitrap fourier transform mass spectrometry. , 2014, Analytical chemistry.

[48]  A. Beck.  Biosimilar, biobetter and next generation therapeutic antibodies , 2011, mAbs.

[49]  Alain Beck,et al.  Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry , 2013, mAbs.